Initiate a Phase 2 clinical trial for COVID-19 gastrointestinal infections
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 10 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“intends to use the net proceeds received from the offering to initiate its two niclosamide clinical programs in the first half of 2021”
What we found
Evidence strength A What the grades mean
Later 10-Q and 10-K filings state the Phase 2 RESERVOIR COVID-19 GI trial was launched or initiated in April 2021, within the first-half 2021 deadline.
-
A AzurRx BioPharma, Inc. 10-K filed 2022-03-31
“In April 2021, we initiated our Phase 2 RESERVOIR clinical trial for the treatment of COVID-19 related GI infections.” ✓ confirmed on the page
-
A AzurRx BioPharma, Inc. 10-Q filed 2021-11-15
“In April 2021, the Company launched the Phase 2 RESERVOIR COVID-19 GI clinical trial using a proprietary oral immediate-release tablet formulation of micronized niclosamide in the U.S., Ukraine and India.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 clinical trial for COVID-19 GI infections
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you AzurRx BioPharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-GRDX-025579 · Corrections policy